AccelDx’s new microfluidic platform, the pScreen allows home testing of biomarker BNP for monitoring of heart failure
Alberto Gandini, PhD, MBA, Co-founder and CEO of Accel Diagnostics, describes the company’s new product, the pScreen for heart failure (HF), at the 4/15/14 Silicon Valley Health 2.0 meet-up. The pScreen allows home testing for blood proteins (biomarkers) at home.
When a drop a body fluid, for example a finger-prick drop of blood is placed in the pScreen, a highly sensitive immunoassay embedded in the platform quantifies the protein in question and displays the result on an easy to read interface which can be photographed, using a cell phone, and sent to a clinician. The first protein the company is testing is BNP or Brain natriuretic peptide, a protein that is elevated in heart failure.
Current methods of monitoring whether patients in the home setting are experiencing exacerbations of heart failure rely mainly on worsening symptoms (e.g., shortness of breath) and weight gain. Most population health management programs for HF utilize home monitoring devices such as electronic scales, telephonic symptom assessment and electronic devices, such as the Health Hero, to collect structured clinical status information from the patient.
If head-to-head clinical trials comparing pScreen with existing approaches demonstrates superiority of this test, it could revolutionize home monitoring of heart failure, replacing fuzzy measures of exacerbation, such as weight gain, with more reliable tests, such as BNP levels.